Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile-Reference-Cited by-同舟云学术

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Published:2017-09-07 Issue:2 Volume:363 Page:240-252
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Barf Tjeerd,Covey Todd,Izumi Raquel,van de Kar Bas,Gulrajani Michael,van Lith Bart,van Hoek Maaike,de Zwart Edwin,Mittag Diana,Demont Dennis,Verkaik Saskia,Krantz Fanny,Pearson Paul G.,Ulrich Roger,Kaptein Allard

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference45 articles.

1. Tec regulates platelet activation by GPVI in the absence of Btk

2. Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks

3. Btk inhibition treats TLR7/IFN driven murine lupus;Bender;Clin Immunol,2016

4. Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

5. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Cited by 306 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-covalent Mechanistic Signatures;2024-09-08

2. Ibrutinib-Related Uveitis: A Case Series from Two Tertiary Centres in the United Kingdom;Ocular Immunology and Inflammation;2024-09-06

3. Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia;Expert Review of Anticancer Therapy;2024-09-02

4. Pyrazine-based small molecule kinase inhibitors: clinical applications and patent review (2019–2023);Future Medicinal Chemistry;2024-08-27

5. Exploring 2-Sulfonylpyrimidine Warheads as Acrylamide Surrogates for Targeted Covalent Inhibition: A BTK Story;Journal of Medicinal Chemistry;2024-08-09